TaiMed Biologics will present at BIO Asia 2025 with encouraging Phase IIa results for its long-acting monoclonal antibody combination therapy, TMB-365/TMB-380. Recently selected as a Late-Breaking Abstract at CROI 2025, the study showed high safety and viral suppression without the need for susceptibility screening—offering a more convenient and effective option for HIV maintenance therapy.

In parallel, TaiMed is pioneering a proprietary Antibody-Drug Conjugate (ADC) platform for HIV. By using monoclonal antibodies with high specificity to CD4+ T cells, this approach delivers antiviral drugs directly to the virus’s target cells while also blocking viral entry, offering dual-action and potential long-lasting control.

Visit TaiMed at Booth #M732 to discover more about our innovations and explore potential collaborations.
Back to the top